Evidence map›Paper›PMID 23622849›Full record

Trial reportJournal of the American Academy of Child and Adolescent Psychiatry2013

Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression.

Robert C Hilton, Manivel Rengasamy, Brandon Mansoor, Jiayan He, Taryn Mayes, Graham J Emslie, Giovanna Porta, Greg N Clarke, Karen Dineen Wagner, Boris Birmaher and 5 more

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Academy of Child and Adolescent Psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00018902 (Treatment of SSRI-Resistant Depression in Adolescents), which is not on this map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00018902 phase2 / phase3completednot on this map

Treatment of SSRI-Resistant Depression in Adolescents (TORDIA)

TypeinterventionalSponsorUniversity of PittsburghRan2001 to 2007Enrolled334ConditionsDepressionArmsFluoxetine, Venlafaxine, Cognitive Behavioral Therapy (CBT), Citalopram
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Anxiety and Depression in Children of Depressed Parents: Dynamics of Change in a Preventive Intervention.Journal of clinical child and adolescent psychology : the official journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 3 countries.

Robert C HiltonSaint Louis University School of Medicine, MO, USA.
Manivel Rengasamy
Brandon Mansoor
Jiayan He
Taryn Mayes
Graham J Emslie
Giovanna Porta
Greg N Clarke
Karen Dineen Wagner
Boris Birmaher
Martin B Keller
Neal Ryan
Wael Shamseddeen
Joan Rosenbaum Asarnow
David A Brent
University of Pittsburgh · USThe University of Texas Southwestern Medical Center · USCleveland Clinic · USJohn Brown University · USKaiser Permanente Center for Health Research · USSaint Louis University · USThe University of Texas at Austin · USThe University of Texas Medical Branch at Galveston · USUniversity of California, Los Angeles · USUniversity of Michigan–Ann Arbor · USWayne State University · US

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
CLINICAL RESEARCH TRAINING IN CHILD PSYCHIATRYT32MH018951 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TINA R GOLDSTEIN · 1990 to 2026
$9.7M
Core--Research network developmentP30MH066371 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BRENT, DAVID A. · 2002 to 2006
$8.2M
TREATMENT OF SSRI RESISTANT DEPRESSION IN ADOLESCENTSU01MH061835 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BRENT, DAVID A. · 2000 to 2006
$3.3M
TREATMENT OF SSRI RESISTANT DEPRESSION IN ADOLESCENTSU01MH061869 · NIMH · KAISER FOUNDATION RESEARCH INSTITUTE · PI CLARKE, GREGORY N · 2000 to 2006
$2.8M
TREATMENT OF SSRI RESISTANT DEPRESSION IN ADOLESCENTSU01MH061856 · NIMH · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI WAGNER, KAREN D · 2000 to 2006
$1.9M
TREATMENT OF SSRI RESISTANT DEPRESSION IN ADOLESCENTSU01MH061958 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI EMSLIE, GRAHAM J. · 2000 to 2006
$1.8M
TREATMENT OF SSRI RESISTANT DEPRESSION IN ADOLESCENTSU01MH061864 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ASARNOW, JOAN ROSENBAUM · 2000 to 2006
$1.5M
TREATMENT OF SSRI-RESISTANT DEPRESSION IN ADOLESCENTSU01MH062014 · NIMH · BROWN UNIVERSITY · PI KELLER, MARTIN B · 2000 to 2006
$1.5M
NCATS NIH HHS UL1 TR000005NIMH NIH HHS MH18951NIMH NIH HHS MH61835NIMH NIH HHS MH61856NIMH NIH HHS MH61864NIMH NIH HHS MH61869NIMH NIH HHS MH61958NIMH NIH HHS MH62014NIMH NIH HHS MH66371NIMH NIH HHS P30 MH066371NIMH NIH HHS T32 MH018951NIMH NIH HHS U01 MH061835NIMH NIH HHS U01 MH061856NIMH NIH HHS U01 MH061864NIMH NIH HHS U01 MH061869NIMH NIH HHS U01 MH061958NIMH NIH HHS U01 MH062014
6 · The paper itself

Abstract

objectiveTo assess the relative efficacy of antidepressant medication, alone and in combination with cognitive behavioral therapy (CBT), on comorbid symptoms of anxiety, attention, and disruptive behavior disorders in participants in the Treatment of Resistant Depression in Adolescents (TORDIA) trial.

methodAdolescents with selective serotonin reuptake inhibitor (SSRI)-resistant depression (N = 334) were randomly assigned to a medication switch alone (to another SSRI or to venlafaxine) or to a medication switch plus CBT. Anxiety, attention-deficit/hyperactivity disorder (ADHD), and disruptive behavior disorder (DBD) symptoms were assessed by psychiatric interview and self-report at regular intervals between baseline and 24 weeks. The differential effects of medication and of CBT, and the impact of remission on the course of comorbid symptoms and diagnoses, were assessed using generalized linear mixed models.

resultsRemission was associated with a greater reduction in scalar measures of anxiety, ADHD, and DBDs, and a greater decrease in the rate of diagnosed anxiety disorders. The correlations between the changes in symptoms of depression on the CDRS-R and anxiety, ADHD, and oppositional symptoms were modest, ranging from r = 0.12 to r = 0.28. There were no significant differential treatment effects on diagnoses, or corresponding symptoms.

conclusionThe achievement of remission had a beneficial effect on anxiety, ADHD, and DBD symptoms, regardless of the type of treatment received. There were no differential effects of medication or CBT on outcome, except for a nonsignificant trend that those adolescents treated with SSRIs showed a greater decrease in rates of comorbid DBDs relative to those treated with venlafaxine. Clinical trial registration information-Treatment of SSRI-Resistant Depression In Adolescents (TORDIA); http://clinicaltrials.gov/; NCT00018902.

Indexed as

AdolescentAnxietyAttention Deficit and Disruptive Behavior DisordersBehavioral SymptomsCitalopramCognitive Behavioral TherapyCombined Modality TherapyComorbidityCyclohexanolsDepressive Disorder, Treatment-ResistantFluoxetineHumansParoxetineRemission InductionSelective Serotonin Reuptake InhibitorsSeverity of Illness IndexCitalopramCyclohexanolsFluoxetineParoxetineSelective Serotonin Reuptake InhibitorsVenlafaxine Hydrochloride

Identifiers

PMID23622849
PMCPMC3756470
OpenAlexW2101273208

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.